At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
In Brief
A Phase 2 clinical trial evaluating PARP Inhibitor BGB-290, Temozolomide, and 1 other intervention for IDH1 Mutation and 4 related conditions. Completed, enrolled 67 participants across 12 sites.
Detailed Summary
This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating patients with recurrent gliomas.
Study Details
Timeline
Interventions
Given PO
Given PO
resection surgery